

## Wednesday, 30 May

9:00 Opening of the meeting

9:15 **The role of the human microbiome on HIV infection**  
**Roger Paredes, MD, PhD**  
*Irsi Caixa Foundation, Barcelona, Spain*

### Session 1 The future of the HIV epidemic in Europe

9:45 **The HIV epidemic in CEE countries**  
**Oana Sandulescu, MD, PhD**  
*Carol Davila University of Medicine and Pharmacy, Bucharest, Romania*

10:15 **HIV transmission in the migrant population**  
**Dimitrios Paraskevis, PhD**  
*National and Kapodistrian University of Athens Medical School, Athens, Greece*

10:45 **How would the epidemic evolve in the future**  
**David van de Vijver, PharmD, PhD**  
*Erasmus Medical Center, Rotterdam, the Netherlands*

11:15 *Discussion*

11:30 Coffee break

### Special session: Improving drug delivery for sustained treatment success

*Chairs: Jonathan Schapiro and Charles Boucher*

12:00 **Improving drug delivery: what are the new technologies?**  
**Saye Khoo, MD, PhD**  
*University of Liverpool, Liverpool, United Kingdom*

12:20 **Long acting HIV drugs for treatment: what are the data?**  
**Anton Pozniak**  
*Chelsea and Westminster Hospital, London, United Kingdom*

12:40 **Long acting HIV drugs for prevention: what are the data?**  
**Pep Coll, MD**  
*Hospital Universitari Germans Trias i Pujol, Badalona, Spain*

13:00 Group picture

13:15 Lunch

### Session 2 Molecular epidemiology of HIV and hepatitis

14:00 **A new wild-type HIV in the era of transmitted drug resistance**  
**Kristof Theys, PhD**  
*University of Leuven, Belgium*



## Abstract - driven presentations:

14:30	Molecular surveillance reveals a recent outbreak of HIV-1 subtype C infections among people who inject drugs (PWID) in Munich, Germany	Norbert Bannert	#1
14:40	Is there a need for HCV resistance testing in routine diagnostics and patient treatment? - Routine HCV genotyping and resistance testing and performance of the Sentosa SQ HCV Genotyping v2.0 assay	Robert Ehret	#2
14:50	The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms	Stephanie Popping	#3
15:05	<i>Discussion</i>		
15:15	Coffee break		


## Session 3 The roll-out of PrEP

15:45	<b>The current status of PrEP in Europe</b> <b>Pep Coll, MD</b> <i>Hospital Universitari Germans Trias i Pujol, Badalona, Spain</i>
16:15	<b>Influence of resistance in the future</b> <b>Richard Harrigan, MD, PhD</b> <i>BC Centre for Excellence in HIV/AIDS, Vancouver, Canada</i>
16:45	<b>Risk compensation in STDs</b> <b>Jade Ghosn, MD</b> <i>Hopital Hotel Dieu, Lyon, France</i>
17:15	<i>Discussion</i>
17:30	<b>Guided poster tour 1: Epidemiology / transmission</b>
18:00	Welcome reception & poster viewing session 1



## Thursday, 31 May

Session 4 Abstract - driven presentations			
08:30	A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors	Quentin Le Hingrat	#4
08:40	Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study	Alexander Thielen	#5
08:50	Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort	Francesca Lombardi	#6
09:00	Dynamics of HIV DNA populations before and after transplantation with CCR5Δ32 stem cells	Annemarie Wensing	#7
09:10	<i>Discussion</i>		
09:30	<b>Guided poster tour 2: Clinical Management of PLWH</b>		
10:00	Coffee break and poster viewing session 2		
10:45	Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings	Maria Santoro	#8
10:55	Characterization of virological failure in HIV-1 infected patients switching to dual therapy with DTG plus one RTI (NRTI or NNRTI)	Nadia Galizzi	#9
11:05	Mutations in the 3'-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo.	Jeroen van Kampen	#10
11:15	<i>Discussion</i>		
Special session: Antiretroviral management: looking towards the horizon			
<i>Chairs: Andrea De Luca and Jonathan Schapiro</i>			
11:30	<b>Clinical trial data 3 vs 2 drug regimens</b> <b>Andrea De Luca, MD</b> <i>University of Siena, Siena, Italy</i>		
11:45	<b>Longer term expectations around resistance</b> <b>Carlo Perno, MD, PhD</b> <i>University of Milan, Milan, Italy</i>		
12:00	<b>Implications for clinical practice</b> <b>Jonathan Schapiro, MD</b> <i>Sheba Medical Center, National Hemophilia Center, Tel Aviv, Israel</i>		
12:15	<i>Panel discussion</i>		
12:30	Lunch		



## Session 5 Roundtable discussion: Bringing the next generation sequencing to the clinic

13:30 **New technologies reaching the clinic**  
**Martin Däumer, MSc**  
*Institute of Immunology and Genetics, Kaiserslautern, Germany*

14:00 **Novel simplified bioinformatics for NGS data analysis**  
**Marc Noguera-Julian, PhD**  
*IrsiCaixa Foundation, Barcelona, Spain*

14:30 *Roundtable Discussion*

15:00 *Coffee break*

## Session 6 Management of viral hepatitis

15:30 **Management of hepatitis C therapy failures - virological perspective**  
**Francesca Ceccherini - Silberstein, PhD**  
*University of Rome "Tor Vergata", Italy*

16:00 **Management of hepatitis C therapy failures - clinical perspective**  
**Sanjay Bhagani, BSc FRCP**  
*Royal Free Hospital, London, United Kingdom*

16:30 **Acute hepatitis A to E, diagnosis and management**  
**Thomas Berg, MD**  
*University Hospital Leipzig, Leipzig, Germany*

### Abstract-driven presentations

17:00 Tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of nucleoside/nucleotide analogs Gule Cinar  
#11

17:10 Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics Slim Fourati  
#12

17:20 Evaluation of pre-treatment risk factors associated with failure in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance Silvia Barbaliscia  
#13

17:30 Can HBV-RNA be useful as a serological marker in patients with antiviral treatment? Presence of HBV-RNA and its correlation with other serological markers. Maria Francesca Cortese  
#14

17:40 *Discussion*

18:00 *End of program Day 2*

19.30 *Group dinner*



## Friday, 1 June

<b>Session 7 What's in the pipeline? Presentations by scientists from the industry</b> <i>Chair: Jonathan Schapiro, Anne-Geneviève Marcelin</i>	
08:30	<b>Romina Quercia, MD, PhD</b> <i>ViiV Healthcare, United Kingdom</i>
08:45	<b>Kathleen Squires, MD</b> <i>Merck, USA</i>
09:00	<b>Kirsten White, PhD</b> <i>Gilead Sciences, USA</i>
09:15	<b>Brinda Emu, MD</b> <i>Theratechnologies / TaiMed Biologics, Yale School of Medicine, USA</i>
09:30	<b>Jean-Marc Steens, MD</b> <i>Abivax, France</i>
09:45	<i>Discussion</i>
10:15	<b>Guided poster tour 3:</b> Hepatitis-related abstracts
10:45	Coffee break
<b>Session 8 Novel therapeutic strategies and prospects for cure</b>	
11:15	<b>Reduced drug regimens</b> <b>Andrea De Luca, MD</b> <i>University of Siena, Siena, Italy</i>
11:45	<b>What is the place of the monoclonal antibodies in the clinic</b> <b>Julià Blanco, PhD</b> <i>IrsiCaixa Foundation, Barcelona, Spain</i>
12:15	<b>Prospects for cure</b> <b>Annemarie Wensing, MD, PhD</b> <i>University Medical Center Utrecht, Utrecht, The Netherlands</i>
12:45	<i>Discussion</i>
13:00	End of the meeting

